This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Spectrum Pharmaceuticals Reports Record Revenues, Profits, And Cash Generated From Operations For The Twelve-Month Period Ended December 31, 2012

Stocks in this article: SPPI

Management uses non-GAAP net income (loss) in its evaluation of the Company's core after-tax results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Management believes that providing these non-GAAP financial measures allows investors to view the Company's financial results in the way that management views the financial results.

The non-GAAP financial measures presented herein have certain limitations in that they do not reflect all of the costs associated with the operations of the Company's business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by the Company may be different from the non-GAAP financial measures used by other companies.

               

Condensed Consolidated Statements of Income and Reconciliation of Non-GAAP Adjustments

(In thousands, except share and per share data)

(Unaudited)

 
Three months ended Year ended
December 31, December 31,
2012       2011 2012       2011
GAAP cost of product sales 15,231 10,283 46,633 33,838
Non GAAP adjustments to cost of product sales:
Zevalin tech transfer 3,826 -- 3,826 --
Total adjustments to cost of product sales 3,826 -- 3,826 --
 
Non-GAAP cost of product sales 11,405 10,283 42,807 33,838
 
 
GAAP selling, general and administrative expenses 27,242 25,292 91,965 72,553
Non GAAP adjustments to G&A:
Reduction in staff 51 -- 1,925 --
Stock-based compensation 4,932 6,572 13,041 20,609
Allos tender offer and Bayer agreement for licensing rights to market ZEVALIN outside the U.S. 108 -- 6,333 --
Total adjustments to G&A 5,091 6,572 21,299 20,609
 
Non-GAAP selling, general and administrative 22,151 18,720 70,666 51,944
 

GAAP research and development

13,887 6,816 42,544 27,720
Non-GAAP adjustments to R&D:
Stock-based compensation 527 449 1,843 1,628
Reduction in staff (28) -- 519 --
One-time payment for co-development agreement -- -- 1,000 --
Total adjustments to R&D 499 449 3,362 1,628
Non-GAAP research and development 13,388 6,367 39,182 26,092
 
 
GAAP amortization of purchased intangibles 2,341 930 6,741 3,720
Non-GAAP adjustments to purchased intangibles:
Amortization 2,341 930 6,741 3,720
Total adjustments to amortization of purchased intangibles 2,341 930 6,741 3,720
Non-GAAP amortization of purchased intangibles -- -- -- --
 
GAAP change in fair value of common stock warrant liability -- -- -- (3,488)
Non-GAAP adjustments to change in fair value of common stock warrant liability:
Change in fair value of common stock warrant liability -- -- -- (3,488)
Non-GAAP change in fair value of common stock warrant liability -- -- -- --
 
GAAP income before income taxes 11,635 9,685 78,980 52,221
Total non-GAAP adjustments 11,757 7,951 35,228 29,445
Non-GAAP income before income taxes 23,392 17,636 114,208 81,666
 
GAAP (provision)/benefit for income taxes (3,014) (1,404) 15,565 (3,704)
Adjustment to (provision)/benefit for income taxes (2,794) -- (37,851) (1,896)
Non-GAAP (provision)/benefit for income taxes (5,808) (1,404) (22,286) (5,600)
 
GAAP net income 8,621 8,281 94,545 48,517
Non-GAAP adjustments 8,963 7,951 (2,623) 27,549
Non-GAAP net income 17,584 16,232 91,922 76,066
 
Non-GAAP income per share:
Basic 0.30 0.29 1.57 1.43
Diluted 0.27 0.26 1.42 1.31
 
Weighted average shares outstanding:
Basic 58,628,963 56,916,064 58,588,916 53,272,767
Diluted 64,020,783 63,313,226 64,637,256 57,959,714
 




7 of 8

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs